Glucosodiene as a Non-Enzymatically Generated Glucose-Derived Glycosidic System: Multi-Scale Reprogramming of the Glycolysis–pH–Glycocalyx Network from Molecular Design to Nanotechnology-Enabled Translational Oncology

Background and Purpose: Tumor progression is sustained by a tightly coupled biochemical network linking aerobic glycolysis, extracellular acidification, and glycocalyx-dependent membrane signaling. This study evaluates glucosodiene, a non-enzymatically generated glucose-derived glycosidic system, as a multi-axis perturbant capable of simultaneously modulating metabolic flux, pH homeostasis, and glycan architecture. Methods: A translational framework was constructed integrating chemical synthesis modeling, spectroscopic validation (¹H NMR, ¹³C NMR, FTIR), nanostructured formulation analysis (glucosodiene-loaded nanoferrites, GLONF), in vitro cytotoxicity assessment, preclinical murine data, and early human case-based observations. Results: Structural analysis supports glucosodiene as a 1→2 glycosidic glucose derivative with preserved hydroxyl-rich architecture and altered stereochemical properties. In vitro, no detectable cytotoxicity was observed in BJ1 fibroblasts up to 100 µg/mL (LC₅₀ not reached). In vivo, GLONF administration (50.4 mg/kg/day) in Ehrlich solid tumor-bearing mice resulted in a significant reduction in tumor weight and size compared to untreated controls (p < 0.01), with the most pronounced effect observed in the post-treatment group. This was accompanied by normalization of hepatic biomarkers, as ALT decreased from 47.0 to 34.8 U/L and AST from 306.4 to 199.0 U/L. Antioxidant systems were restored, with GSH increasing from 0.67 to 2.07 mmol/g and SOD from 58.7 to 97.7 U/g, alongside a marked reduction in lipid peroxidation, reflected by a decrease in MDA from 166.8 to 79.1 nmol/g. Molecular analysis demonstrated attenuation of proliferative signaling (PCNA) and modulation of p53-associated stress response pathways. Early clinical observations (n = 3) showed rapid symptomatic improvement by day 5 and metabolically favorable imaging responses within 15–20 days, including PET-documented regression and biomarker reduction, where ALP declined from 700 to 280 U/L and CA15-3 from 146.6 to 78.1 KU/L. Mechanistic Interpretation: Glucosodiene is proposed to reduce effective glycolytic throughput, attenuate lactate-driven extracellular acidosis, and disrupt glycocalyx integrity via altered glycosylation dynamics, thereby reconditioning tumor metabolic and signaling states. Conclusion: Glucosodiene represents a glucose-derived systems-level perturbant targeting the integrated metabolism–microenvironment–glycocalyx network, warranting further mechanistic and translational validation.